PLx Pharma Winddown Corp. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
PLx Pharma Winddown Corp. had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $4.71 million as of 2021-12-31, per its 10-K filed 2022-03-11.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2022-03-11
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.71M.
- 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.90M; Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed $4.90M.
- 2019-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.51M.
- 2018-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.77M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2021-12-31 | $4.71M 10-K · filed 2022-03-11 | |
| 2020-12-31 | $4.90M 10-K · filed 2022-03-11 | $4.90M 10-K · filed 2021-03-12 |
| 2019-12-31 | $4.51M 10-K · filed 2021-03-12 | |
| 2018-12-31 | $3.77M 10-K · filed 2020-03-13 | |
| 2017-12-31 | $3.09M 10-K · filed 2019-03-08 | |
| 2016-12-31 | $922.46K 10-K · filed 2018-03-23 | $3.58M 10-K · filed 2017-01-20 |
| 2015-12-31 | $2.02M 10-K · filed 2017-01-20 | |
| 2014-12-31 | $588.86K 10-K · filed 2016-03-22 |